Sudarshan Pharma: Acquisition of Med Therapy Stake Under Due Diligence

Sudarshan Pharma Industries Ltd has provided an update regarding its proposed acquisition of 9.50% equity shares in Med Therapy Biotechnology Inc., USA. The acquisition is currently under due diligence, and the decision and resolutions from Med Therapy's Board of Directors are still pending. Similarly, the proposed acquisition of 1.50% equity shares each by promoters Mr. Hemal Mehta and Mr. Sachin Mehta is also undergoing due diligence with pending board approvals from Med Therapy. The company expects to provide further updates soon.